InvestSMART

Starpharma Holdings Limited (ASX:SPL)

ALERT: Price-sensitive ASX Announcement for SPL
Current share price for SPL : $0.735 -0.02 (-2.65%)+
Announcement
Release
15 Jul 2026 9:10AM
Price at Release
$0.755
Full Release
download
Summary
Starpharma Holdings Limited has announced a fully underwritten entitlement offer to raise approximately $32 million by issuing around 56 million new ordinary shares at an issue price of $0.57 per share. This offer is intended to strengthen the company's balance sheet with an expected pro forma cash balance of $44.5 million as of 30 June 2026. The proceeds will extend the cash runway into FY28 and support the DEP® HER2-Lu Phase 1 study while accelerating the development of new dendrimer-based oncology assets. Eligible shareholders in several countries are invited to subscribe for one new share for every 7.5 existing shares held on the record date. The offer is managed by Canaccord Genuity (Australia) Limited, and no prospectus is prepared as the offer relies on a specific section of the Corporations Act.
Key Points
  • Fully underwritten renounceable entitlement offer to raise approximately $32 million.
  • Issue price of $0.57 per share, offering around 56 million new shares.
  • Proceeds to extend cash runway into FY28, supporting DEP® HER2-Lu Phase 1 study.
  • Offer structure allows one new share for every 7.5 existing shares held.
  • Canaccord Genuity (Australia) Limited appointed as lead manager and underwriter.
  • Offer does not require a prospectus, relying on Corporations Act section 708AA.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.